Two Arms of a System Usually Taught as One
Most textbook teaching of the renin-angiotensin system (RAS) focuses on the ACE → Angiotensin II → AT1 receptor axis — vasoconstriction, aldosterone release, fluid retention, inflammation. What the textbook treatment often underemphasizes is that this axis has a parallel counter-regulatory arm: ACE2 → Angiotensin(1-7) → Mas receptor, which produces the opposite effects.
The research-grade peptide is available as Angiotensin(1-7) 10mg.
ACE2: The Counter-Regulatory Enzyme
ACE2 (angiotensin-converting enzyme 2) shares ~40% homology with ACE but produces different products. Where ACE generates angiotensin II (vasoconstrictor), ACE2 cleaves angiotensin II into angiotensin(1-7) — converting the bad-arm mediator into the good-arm mediator.
The same enzyme balance:
- High ACE activity → Ang II accumulation → AT1R activation → vasoconstriction, inflammation
- High ACE2 activity → Ang(1-7) accumulation → MasR activation → vasodilation, anti-inflammation
The Mas Receptor
Mas (MAS1) is a GPCR with high specificity for Ang(1-7). Signaling includes:
- Vasodilation via NO release and prostaglandin signaling
- Anti-fibrotic effects through TGF-β pathway modulation
- Anti-proliferative signaling via MAPK pathway downregulation
- Anti-inflammatory effects on immune cells
Each effect is the opposite of what AT1R activation produces — hence "counter-regulatory."
Research Domains
Angiotensin(1-7) research spans:
- Cardiovascular: Hypertension models, cardiac remodeling research
- Renal: Anti-fibrotic kidney research
- Pulmonary: ACE2/Ang(1-7) axis in lung injury models (heavily studied post-2020)
- Metabolic: Insulin sensitivity and adipose research
- Oncology: Anti-proliferative research in certain tumor models
The Short Half-Life Challenge
Angiotensin(1-7) has a short plasma half-life (~30 seconds) in vivo due to rapid peptidase cleavage. Research protocols address this through:
- Continuous infusion in acute pharmacology studies
- Oral cyclodextrin formulations that extend exposure
- Analog development with peptidase resistance
Most research-grade Ang(1-7) work uses acute protocols that tolerate the short duration — the half-life is a research variable rather than a blocker.
Pairing With Repair Compounds
Angiotensin(1-7) pairs cleanly with other repair-oriented research peptides (BPC-157, TB-500) because the anti-fibrotic and vasodilatory mechanisms are non-overlapping with NO/VEGF or actin-dynamics pathways.
Handling
Standard lyophilized peptide handling — −20°C, bacteriostatic water reconstitution, >98% HPLC purity. See Angiotensin(1-7) 10mg for the research vial.